secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2023-05-25T23:59:59+00:00
Accession:  0001140361-23-026621
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 3.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO Peter Hecht invests $5M in Cyclerion; receives 225K common shares and 351K Series A convertible preferred
--------------------------------------------------------------------------------

- Peter Hecht, CEO, purchased $5M in equity at $8.68 per share (post-1-for-20 reverse split).
- Issued 225,000 shares of common stock and 351,037 shares of Series A convertible preferred (1:1 conversion).
- Hecht agreed not to convert preferred if it would require Nasdaq shareholder approval.
- Transaction completed May 19, 2023; exempt from registration under Regulation D and Section 4(a)(2).
- Filed Articles of Amendment to designate Series A Preferred Stock; no shareholder approval needed for issuance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000114036123026621/0001140361-23-026621-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000114036123026621/brhc20053546_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-026621

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer